NeoGenomics names Warren Stone CEO effective Jan 4, 2027; Zook to Executive Chair; Q3 revenue ~$209M

NEOGENOMICS INC

Warren Stone, President & COO since April 2025, becomes CEO and board member effective January 4, 2027; Tony Zook moves from CEO to Executive Chairman the same day.
Stone's employment agreement: $850,000 base salary, 100% target bonus, and annual equity awards with aggregate target value ~$8,000,000 beginning FY2027.
Zook's amended agreement: $400,000 base salary, 50% target bonus, and annual restricted stock unit awards with target value ~$3,000,000.
Board Chair Lynn Tetrault steps down January 4, 2027, remains an independent director until the 2027 annual meeting and won't stand for reelection; Michael Kelly becomes Lead Independent Director.
Preliminary Q3 2026 revenue ~$209M with NGS revenue up ~28% YoY; FY revenue and adjusted EBITDA guidance reiterated from July 28, 2026, with midpoint revenue expected to rise.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.